ALPN News and Press, Alpine Immune Sciences Inc. From 11/13/19

Company Advancing ALPN-101 into a Phase 1/2 Acute Graft versus Host Disease Study (BALANCE) Phase 1 Study (NEON-1) of Lead Oncology Program ALPN-202 Planned to Commence in Q1 2020 Conference Call Scheduled for 4:30 p.m. ET Today Alpine Immune Sciences, Inc. (NASDAQ:ALP...

ALPN-101 is distinct from the other biologic therapies and superior to combination biological blockade Preclinical activity suggests unique effectiveness across a range of rheumatic and other inflammatory diseases Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-sta...

  Preclinical data support unique mechanism of action of ALPN-202 as a first in class conditional CD28 Agonist ALPN-202 able to increase CD8+ T-cells in tumors ALPN-202 has potent monotherapy activity and significantly improves upon the activity of multiple anticancer therapie...

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced an abstract has been accepted for an oral presentation highlighting the companyȁ...

Company to Discuss Topline Results and Provide Company Update on Third Quarter 2019 Conference Call and Webcast Scheduled for November 13, 2019 at 4:30 p.m. ET Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a clinical-stage immunotherapy company focused on developing innovative treatmen...

Gainers:  Tiffany & Co. (NYSE: TIF ) +31% . Xunlei Limited (NASDAQ: XNET ) +27% . Datasea (NASDAQ: DTSS ) +25% . comScore (NASDAQ: SCOR ) +24% . Fitbit (NYSE: FIT ) +23% . Aquestive Therapeutics (NASDAQ: AQST ) +23% . ChinaNet Online Holdings (NASDAQ: CNET ) +20% . Libbey (...

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced planned poster presentations at upcoming scientific meetings highlighting new preclin...

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will present at the 2019 Ladenburg Thalmann Healthcare Conference on Tues...

Gainers : DPW Holdings, Inc. (NYSEMKT: DPW ) +217% . Yuma Energy (NYSEMKT: YUMA ) +210% . DryShips (NASDAQ: DRYS ) +35%.  TrovaGene (NASDAQ: TROV ) +32% . Qiwi (NASDAQ: QIWI ) +22% . Houston Wire & Cable (NASDAQ: HWCC ) +22%.  China Green Agriculture (NYSE: CGA ) +21%....

The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) had an active week, opening at 3,298.28 points on Monday (August 12) and reaching a high of 3,338.66 points on Tuesday (August 13). Throughout the rest of the period, the index continued dropping before settling at 3,290.75 points as of 1:1...